- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
November 20, 2024Eighth Circuit Affirms U.S. Merchants Victory in Trade Dress Infringement Case
-
November 15, 2024Lauren Coppola Named an Emerging Leader by Profiles in Diversity Journal
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Purdue Pharma L.P. v. Accord Healthcare Inc.
OxyContin® (oxycodone HCl)
September 8, 2023
Case Name: Purdue Pharma L.P. v. Accord Healthcare Inc., C.A. No. 22-913-WCB, 2023 WL 5835811 (D. Del. Sept. 8, 2023) (Bryson, J.)
Drug Product and Patent(s)-in-Suit: OxyContin® (oxycodone HCl); U.S. Patents Nos. 11,304,908 (“the ’908 patent”) and 11,304,909 (“the ’909 patent”)
Nature of the Case and Issue(s) Presented: The patents-in-suit claim tablet formulations that are “tamper resistant.” Specifically, they claim technology that makes oxycodone HCl tablets that are “hard enough to resist crushing by abusers and viscous enough to deter intravenous abuse by abusers who manage to crush the tablets into particles and mix with water for injection.” In a prior action, Accord I, three patents in the same family as the patents-in-suit were held invalid as obvious. Accord moved for judgment on the pleadings, arguing that Purdue is barred from asserting the claims of the patents-in-suit because those claims are invalid for obviousness due to collateral estoppel from court’s findings in Accord I action. Accord’s motion was denied.
Why Defendants Prevailed: Purdue’s principal arguments were that: (i) Accord’s motion impermissibly asks the court to take judicial notice of the Accord I trial record; and (ii) Accord failed to demonstrate that collateral estoppel applied to the claims in this case. The court disagreed with the former and agreed with the latter.
Regarding the judicial notice argument, Purdue does not dispute that a court may take judicial notice of a prior proceeding, but argued that at the pleading stage the court may take notice of only the existence of the opinion, not for the truth of the facts asserted in the opinion. The court disagreed, citing extensive case law standing for the proposition that “[i]n the context of deciding a Rule 12(b)(6) motion that raises issue preclusion concerns ... it is axiomatic that a court must still consider the prior adjudication in order to determine whether issue preclusion bars that plaintiff’s claims.” In deciding that the court may take judicial notice of the earlier trial record, it noted that judicial notice did not extend to the evidence presented to the court at trial or transcripts of the proceedings that took place during the action.
Regarding the collateral estoppel argument, each of the independent claims in the patents-in-suit required “a plurality of convection heated particles of PEO [polyethylene oxide]” that “adhere to or fuse with each other within the matrix.” That limitation was not expressly recited in the claims in Accord I, and Judge Andrews did not discuss or decide whether the prior art asserted in that case disclosed that limitation. In response, Accord argued that those limitations were the inherent result of heating the PEO matrix as described in the prior art asserted in Accord I. But as noted, testimony offered during a prior proceeding cannot be the subject of judicial notice for purposes of finding facts. Moreover, finding inherency is a high standard. The statements in the shared specification of the patents-in-suit and those found invalid in Accord I related to curing and heating PEO are suggestive at best, which is insufficient to establish inherency. “As the specification demonstrates, a number of variables exist in the manufacturing process, such as the use of direct compression, the order and sequencing of compression and curing, the percentage of PEO that melts, the curing temperature and time, the use of a cooling step, and the equipment used in manufacturing.” Because the specification did not state or even imply that adherence and/or fusion is an inherent result of every combination of variables that involve curing PEO at a temperature above its softening temperature, and Judge Andrews did not decide any such questions in his Accord I opinion, those are factual matters that should be reserved for trial in the instant case.
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.